Expression of Hematological Markers in Breast Cancer Subtypes: Prognostic and Therapeutic Relevance
DOI:
https://doi.org/10.62059/LatArXiv.preprints.473Keywords:
Breast cancer, Hematology, Thrombocytosis, PrognosisAbstract
Background: Breast cancer involves complex interactions with hematologic parameters. Indicators like NLR, thrombocytosis, and IL-6 levels reflect immune dynamics and clinical trajectories. Objective: To evaluate the predictive value of hematological biomarkers for prognosis and treatment response in breast cancer patients. Methods: A longitudinal observational study of 76 patients was conducted. NLR, platelet count, hemoglobin, and IL-6 levels were measured and correlated with tumor subtype, clinical response, and 2-year survival. Results: High NLR (>4) was linked to poorer treatment response and increased recurrence (p<0.01). Thrombocytosis prevailed in HER2+ and triple-negative subtypes. Elevated IL-6 was associated with chemoresistance. Discussion: Findings confirm that hematologic markers offer insight into tumor microenvironments. Their inclusion in care protocols could enhance patient stratification, treatment planning, and post-treatment monitoring with minimal resource demand. Conclusions: Hematological biomarkers represent valuable prognostic tools in breast oncology. Their use may promote personalized therapy, improve recurrence prediction, and support interdisciplinary approaches in breast cancer management.
References
Doddagowda MS, Raju K, Kalyani PN, Sreeramulu N. Prognostic value of pre-treatment routine hematological parameters in breast
carcinoma. Biomed Res Ther. 2020;7(8):3916–3920. https://bmrat.com/index.php/BMRAT/article/view/621
Coradi C, Panis C. Harnessing hematological ratios: prognostic insights for breast cancer management. Clin Transl Oncol. 2024;27:2041– 2053. https://link.springer.com/article/10.1007/s12094-024-03721-z
Zhou Q, Dong J, Sun Q, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker in breast cancer receiving neoadjuvant chemotherapy: a meta-analysis. BMJ Open. 2021;11(9):e047957. https://bmjopen.bmj.com/content/11/9/e047957
Corbeau I, Jacot W, Guiu S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic
review. Cancers. 2020;12(4):958. https://www.mdpi.com/2072-6694/12/4/958
Ocaña A, Chacón JI, Calvo L, et al. Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant
chemotherapy in breast cancer. Front Oncol. 2022;11:82762. https://www.frontiersin.org/articles/10.3389/fonc.2021.827625/full
Guo Z, Zhang H, Fu Y, et al. Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell Death Discov. 2023;9:6. https://www.nature.com/articles/s41420-023-01306-3
Liu H, Yan R, Xiao Z, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer
by inhibiting IL-6/STAT3 signaling. Breast Cancer Res. 2023;25:43. https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-023-01642-3
Manore SG, Doheny DL, Wong GL, Lo HW. IL-6/JAK/STAT3 signaling in breast cancer metastasis: biology and treatmen Oncol. 2022;12:866014. https://www.frontiersin.org/articles/10.3389/fonc.2022.866014/full
Soler MF, Abaurrea A, Azcoaga P, et al. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother
Cancer. 2023;11:e007530. https://jitc.bmj.com/content/11/11/e007530
Mohamed AH, Ahmed AT, Al Abdulmonem W, et al. Interleukin-6 serves as a critical factor in various cancer progression and therapy. Med Oncol. 2024;41:182. https://link.springer.com/article/10.1007/s12032-024-02422-5
Piñón LA, Lara AJ, Costa JA, et al. Thrombocytosis as a prognostic factor in patients with breast, colon and lung cancer. Scholastic Med Sci. 2024;1(4):1–3. https://www.scholasticopenaccess.org/uploads/SCMS-02-0027.pdf
Chen L, Kong X, Yan C, et al. Prognostic value of common hematological parameters in peripheral venous blood in breast cancer.
Onco Targets Ther. 2020;13:1397–1412. https://www.dovepress.com/the-research-progress-on-the-prognostic-value-of-the-common-hematologi-peer-reviewed-fulltext-article-OTT
Giannakeas V, Kotsopoulos J, Cheung MC, et al. Analysis of platelet count and new cancer diagnosis over a 10-year period. JAMA
Netw Open. 2022;5(1):e2141634. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787932
Rajkumar A, Szallasi A. Paraneoplastic thrombocytosis in breast cancer. Anticancer Res. 2013;33(10):4545–4546. https://ar.iiarjournals.org/content/33/10/4545
Tatsumi K. The pathogenesis of cancer-associated thrombosis. Int J Hematol. 2024;119:495–504. https://link.springer.com/article/10.1007/s12185-024-03735-x
Huang RS, Li X, Haberberger J, et al. Biomarkers in breast cancer: an integrated analysis of comprehensive genomic profiling and
PD-L1 immunohistochemistry. Oncologist. 2020;25(11):943–953. https://academic.oup.com/oncolo/article/25/11/943/6443253
Lopez-Gonzalez L, Sanchez Cendra A, Roberts Cervantes ED, et al. Exploring biomarkers in breast cancer: hallmarks of diagnosis
treatment, and follow-up. Medicina. 2024;60(1):168. https://www.mdpi.com/1648-9144/60/1/168
Kalbasi A, Ribas A. Resistance to immune checkpoint blockade: mechanisms and strategies. Nat Rev Cancer. 2020;20(11):651–668.
https://www.nature.com/articles/s41568-020-00324-9
Choong GMY, et al. The impact of adjuvant endocrine therapy omission in ER-low early-stage breast cancer. ASCO 2024 Abstract 505.
UCLA Health. SABCS 2024: Improved survival for advanced breast cancer using targeted therapies. https://www.uclahealth.org/news/release/sabcs-improved-survival-advanced-breast-cancer-using
Downloads
Downloads
Posted
Categories
Data Availability Statement
Los datos utilizados en esta investigación están disponibles previa solicitud razonable al autor correspondiente. Debido a consideraciones éticas y de confidencialidad clínica, no se encuentran depositados en repositorios públicos. Para acceder a ellos, las personas interesadas pueden contactar a través del correo electrónico: [email protected].
License
Copyright (c) 2025 Anelys García Salgado, Dr Nelson, Dr Marlon, Dra Anadely (Autor/a)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This preprint contains the reported license and associated copyright. Once published in an associated journal or other publisher, the published version assumes the publisher's terms and conditions.
